medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2016, Número 1

<< Anterior Siguiente >>

Residente 2016; 11 (1)


Enfermedad aterosclerótica coronaria en artritis reumatoide

Olvera-Palafox CN, Flores-Chávez A, Romero-Moreno JR, Cardona-Müller D, Trujillo-Trujillo X, González-López L

Idioma: Español
Referencias bibliográficas: 50
Paginas: 19-27
Archivo PDF: 248.44 Kb.


RESUMEN

En el mecanismo de la aterosclerosis subclínica en pacientes con AR, se ha descrito la influencia tanto de la presencia de factores de riesgo tradicionales como el proceso inflamatorio y los mecanismos autoinmunes. Los autoanticuerpos, los autoantígenos, citocinas proinflamatorias y agentes infecciosos juegan un importante papel en este proceso. En la AR, se ha observado un incremento en la incidencia de la aterosclerosis acelerada; en pacientes con AR, la función vascular se encuentra alterada y el proceso de aterosclerosis parece estar acelerado debido a diversos factores, como el incremento de la rigidez arterial, las reducciones de la elasticidad arterial, el deterioro en la respuesta endotelial, el incremento del grosor de la íntima-media y el contenido de calcio coronario, los cuales se ven modificados debido a la presencia de la inflamación severa presente en estos sujetos y, a su vez, representan un incremento en el riesgo de morbilidad y mortalidad cardiovascular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001; 358 (9285): 903-911.

  2. Rodríguez MA. Artritis reumatoide. En: Alarcón SD, Molina LJ (editores). Tratado hispanoamericano de reumatología. Bogotá: Editorial Nomos; 2006. pp. 435-500.

  3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094-108.

  4. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res ClinRheumatol. 2002; 16 (5): 707-722.

  5. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J et al. Grupo de Estudio Epidemiológico de Enfermedades Músculo Articulares (GEEMA). Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

  6. Scarno A, Perrotta FM, Cardini F et al. Beyond the joint: subclinical atherosclerosis in rheumatoid arthritis. World J Orthop. 2014; 5 (3): 328-335.

  7. Aviña-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59: 1690-1697.

  8. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008; 121: S21-S31.

  9. Meune C, Touzé E, Trinquart L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Reumatology. 2009; 48 (10): 1309-1313.

  10. Choi HK, Rho Y-H, Zhu Y et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013; 72 (7): 1182-1187.

  11. Choy E, Sattar N. Interpreting lipids levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009; 68: 360-469.

  12. Solomon DH, Karlson EW, Rimm EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107: 1303-1307.

  13. Goodson NJ, Silman AJ, Pattison DJ et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford). 2004; 43: 731-736.

  14. Del Rincón I, Polak JF, O’Leary DH et al. Systemic inflammation and cardiovascular risk factor predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015; 74 (6): 1118-1123.

  15. Deo SS, Chogle AR, Mistry KJ et al. Increased prevalence of subclinical atherosclerosis in rheumatoid arthritis patients of Indian descent. Exp Clin Cardiol. 2012; 17 (1): 20-25.

  16. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014; 53: 2143-2154.

  17. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011; 63 (11): 3216-3225.

  18. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other inflammatory arthritis. Ann Rheum Dis. 2010; 69 (2): 325-331.

  19. Koivuniemi R, Paimela L, Suomalainen R et al. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatoil. 2013; 42 (2): 131-135.

  20. Zinger H, Sherer Y, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases –mechanisms and clinical findings. Clin Rev Allergy Immunol. 2009; 37 (1): 20-28.

  21. Bartoloni E, Alunno A, Bistoni O et al. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev. 2010; 9 (10): 701-707.

  22. Ku IA, Imboden JB, Hsue PY et al. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J. 2009; 73 (6): 977-985.

  23. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis. 2002; 46: 862-873.

  24. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767-1772.

  25. Ridker P, Hennekens C, Roitman-Johnson B et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998; 351: 88-92.

  26. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-2168.

  27. Molrnaar E, Voskuyl A, Familian A, Van Mierlo G, Dijkmans B, Hack C. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001; 44: 997-1002.

  28. Meek RL, Urieli-Shoval S, Benditt E. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA. 1994; 91: 3186-90.

  29. Lazarevic MB, Vitic J, Mladenovic V et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992; 22: 172-178.

  30. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol. 2000; 19: 324-325.

  31. Hernanz A, Plaza A, Martín-Mola E et al. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999; 32: 65-70.

  32. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100: 2124-2126.

  33. Turesson C, McClelland RL, Christianson TJ. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 70-75.

  34. Jacobsson LT, Turesson C, Hanson RL et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 2001; 44: 1170-1176.

  35. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233-241.

  36. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051.

  37. Pasceri V, Willerson J, Yeh. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-2168.

  38. Meek R, Urieli-Shoval S, Benditt E. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. ProcNatlAcadSci USA. 1994; 91: 3186-90.

  39. James M, van Reyk D, Tye K et al. Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized. Lipids. 1998; 33: 1115-1121.

  40. Winyard P, Tatzber F, Esterbauer H et al. Presence of foam cells containing oxidized low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis. 1993; 52: 677-680.

  41. Kume N, Murase T, Moriwaki H et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998; 83: 332-337.

  42. Nagase M, Abe J, Takahashi K et al. Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-) gene. J Biol Chem. 1998; 272: 33702-33707.

  43. Memon R, Staprans Y, Noor M et al. Infection and inflammation induce LDL oxidation in vivo. Arterioescler Thromb Vasc Biol. 2000; 20: 1536-1542.

  44. Canalizo-Miranda E, Favela-Pérez EA, Salas-Anaya JA et al. Guía de práctica clínica: diagnóstico y tratamiento de las dislipidemias. Rev Med Inst Mex Seg Soc. 2013; 51 (6): 700-709.

  45. Ministry of Health. Clinical practice guidelines. Lipids. Singapore: Ministry of Health; 2006.

  46. Scott M, Grundy MD, Becker D, Clark LT et al. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood colesterol in adults. Adult Treatment Panel III. NIH. 2002; 2: V1-V28.

  47. Castro-González MI. Ácidos grasos omega 3: beneficios y fuentes. Redalyc. 2002; 27 (3): 128-136.

  48. Escudero-Alvarez E, González-Sanchez P. La fibra dietética. NutrHosp. 2006; 21 (2): 61-72.

  49. Fischer LM, Schlienger RG, Matter CM. Discontinuation of non steroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med. 2004; 164: 2472-2476.

  50. Fonarow GC. Aggressive treatment of atherosclerosis: the time is now. Cleve Clin J Med. 2003; 70 (5): 431-434, 437-438, 440.




2020     |     www.medigraphic.com